drugset / Trial / NCT07305974
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Phase 2
Recruiting
30 enrolled
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is being given.
Timeline
- Start
- 2025-09-08
- Primary completion
- 2029-03-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RG002C0106 | Small interfering RNA (siRNA) | — | Subcutaneous |